Scancell Hlds (SCLP) - Result of AGM
RNS Number : 5880Q
Scancell Holdings Plc
07 November 2012
7 November 2012
Scancell Holdings Plc
Result of AGM
Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer
vaccines, announces that at the Annual General Meeting, held yesterday, all
resolutions were duly passed.
Scancell is developing therapeutic vaccines for the treatment of cancer and
infectious diseases based on its ImmunoBody® and Moditope™ technology
platforms. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma.
Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the
cellular immune system; the helper cell system where inflammation is
stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response
where immune system cells are primed to recognise and kill specific cells.
A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo,
pulsing them with tumour antigens and re-infusing them. However, this
procedure is patient specific, time consuming and expensive. Scancell has
developed its breakthrough patent protected ImmunoBody® technology to overcome
Scancell has also identified and patented a series of modified epitopes that
stimulate the production of killer CD4 that destroy tumours without toxicity.
The Directors believe that the Moditope™ platform could have a profound effect
on the way that cancer vaccines are developed.
The Directors of the issuer accept responsibility for this announcement.
For Further Information:
Scancell Holdings Plc + 44 (0) 74 2323 0497
Dr Richard Goodfellow, Joint CEO
Professor Lindy Durrant, Joint CEO
Visible Value LLP: + 44 (0) 74 2323 0497
Annie Cheng, CFA firstname.lastname@example.org
Cenkos Securities: +44 (0) 20 7397 8900
This information is provided by RNS
The company news service from the London Stock Exchange
RAGBUBDBCUGBGDR -0- Nov/07/2012 16:02 GMT
Press spacebar to pause and continue. Press esc to stop.